Mohammad Azimi
Research Subjects
Research Interests
Mohammad Azimi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Dana Neitzel
Good Start Genetics, Inc. 237 Putnam Ave. Cambridge MA
1 shared publicationKyle Schmaus
Evidera 450 Sansome Street Suite 650 San Francisco CA
1 shared publicationRobert Rochelle
Good Start Genetics, Inc. 237 Putnam Ave. Cambridge MA
1 shared publicationTuan Dinh
Evidera 450 Sansome Street Suite 650 San Francisco CA
1 shared publication- Valerie Greger
Good Start Genetics, Inc., Cambridge, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 29 January 2016
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 4 (3) , 292-302
Carrier screening by next‐generation sequencing: health benefits and cost effectiveness
Background: Compared with conventional genotyping, which typically tests for a limited number of mutations, next‐generation DNA sequencing (NGS) provides increased accuracy for carrier screening. The objective of this study was to evaluate the cost effectiveness of carrier screening using NGS versus genotyping for 14 of the recessive disorders for which medical society guidelines recommend screening.Methods: Data from published literature, population surveys, and expert opinion were used to develop a decision tree model capturing decisions and outcomes related to carrier screening and reproductive health.Results: Modeling a population of 1,000,000 couples that was representative of the United States population and that contained 83,421 carriers of pathogenic mutations, carrier screening using NGS averted 21 additional affected births as compared with genotyping, and reduced costs by approximately $13 million. As compared with no screening, NGS carrier screening averted 223 additional affected births. The results are sensitive to assumptions regarding mutation detection rates and carrier frequencies in multiethnic populations.Conclusion: This study demonstrated that NGS‐based carrier screening offers the greater benefit in clinical outcomes and lower total healthcare cost as compared with genotyping.
- 29 January 2016
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 4 (3) , 292-302
Open AccessCarrier screening by next‐generation sequencing: health benefits and cost effectiveness
Background: Compared with conventional genotyping, which typically tests for a limited number of mutations, next‐generation DNA sequencing (NGS) provides increased accuracy for carrier screening. The objective of this study was to evaluate the cost effectiveness of carrier screening using NGS versus genotyping for 14 of the recessive disorders for which medical society guidelines recommend screening.Methods: Data from published literature, population surveys, and expert opinion were used to develop a decision tree model capturing decisions and outcomes related to carrier screening and reproductive health.Results: Modeling a population of 1,000,000 couples that was representative of the United States population and that contained 83,421 carriers of pathogenic mutations, carrier screening using NGS averted 21 additional affected births as compared with genotyping, and reduced costs by approximately $13 million. As compared with no screening, NGS carrier screening averted 223 additional affected births. The results are sensitive to assumptions regarding mutation detection rates and carrier frequencies in multiethnic populations.Conclusion: This study demonstrated that NGS‐based carrier screening offers the greater benefit in clinical outcomes and lower total healthcare cost as compared with genotyping.